molecule should be chemically unique, without evidence of previous pharmacological
development.
Selected ReferencesDesigning a Lead Compound
D. Baker, A. Sali (2001). Protein structure prediction and structural genomics. Science 294:
93–96.
F. A. Bisby (2000). The quiet revolution: biodiversity informatics and the internet.Science 289:
2309–2312.
S. Borman (2000). Combinatorial chemistry: redefining the scientific method for drug discovery.
Chem. Eng. News 78: 53–66.
A. S. V. Burgen and G. C. K. Roberts (Eds.) (1986). Molecular Graphics and Drug Design.
Topics in Molecular Pharmacology, vol. 3. Amsterdam: Elsevier.
N. C. Cohen (1983). Towards the rational design of new leads in drug research. Trends
Pharmacol. Sci. 4 : 503–506.
J. Drews (2000). Drug discovery: a historical perspective. Science 287: 1960–1964.
A. Edwards, C. Arrowsmith, B. Pallieres (2000). Proteomics: new tools for a new era. Mod. Drug
Discov. 3: 34–45.
C. Ezzell (2002). Proteins rule. Sci. Amer. 286: 40–47.
J. Gasteiger (2003). Handbook of Chemoinformatics. New York: Wiley.
C. Henry (2001). Pharmacogenomics. Chem. Eng. News 79: 37–45.
A. J. Hopfinger (1985). Computer-assisted drug design. J.Med. Chem. 28: 1133–1139.
P. N. Kant, P. Daftari (1986). Marine pharmacology: bioactive molecules from the sea. Annu. Rev.
Pharmacol. Toxicol. 26: 117–142.
DESIGNING DRUG MOLECULES TO FIT RECEPTORS 163Figure 3.11Failure of drug molecules. Many drugs that are successful in the pharmacodynamic
phase ultimately fail to become useful drugs. This pie-chart presents the reasons for failure at this
stage of the development process. Toxicity is an important cause of failure.